How the University of California is fighting proxy patent battle for expensive cancer drug in India
The following is taken from an article originally published in The Wire. It has been reprinted here with permission from the author. The original can be accessed here. New Delhi: Xtandi is a life-prolonging cancer drug and sells at about Rs 2.7 lakh for a month’s course in India – that’s for four tablets daily. It …
